drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy that targets and eliminates CD19+ B cells to reduce autoantibody production and humoral immune activation.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Obecabtagene Autoleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a CD19-specific chimeric antigen receptor bind CD19 on B cells and plasmablasts, activate cytotoxic effector functions, and deplete CD19+ B cells, thereby reducing autoantibody production and humoral immune activation.
drug_name
Obecabtagene autoleucel (obe-cel; AUTO1)
nct_id_drug_ref
NCT06333483